| Project/Area Number |
16K18463
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Tumor therapeutics
|
|---|
| Research Institution | Kawasaki Medical School |
|---|
Principal Investigator |
|
|---|
| Research Collaborator |
Oka MIKIO 川崎医科大学, 医学部・呼吸器内科学, 教授 (40223995)
Kurose KOJI 川崎医科大学, 医学部・呼吸器内科学, 臨床助教 (30551139)
|
|---|
| Project Period (FY) |
2016-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2017: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2016: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | 肺がん / がん抗原 / 免疫療法 / 免疫チェックポイント分子 / 肺癌 / XAGE1 / PD-1 / TIM-3 / Galectin-9 / 免疫チェックポイント / 癌 / 免疫活性化 |
|---|
| Outline of Final Research Achievements |
The effect of immunotherapy in lung cancer is still insufficient, and elucidation of new immunosuppressive mechanism is important. In this study, expression of PD-1 and TIM-3 on tumor-infiltrating T cells and expression of their ligands on tumor cells were examined and analyzed for correlation with survival. Expression of PD-L1 and galectin-9 and XAGE 1 antigens on tumor cells were independent prognostic factors of TNM classification (HR: 0.40, p = 0.01).
Based on the above results, the survival of patients with lung adenocarcinoma can be predicted by investigating the tumor microenvironment in detail. Furthermore, in addition to the PD-1 / PD-L1 pathway, the TIM-3 / galectin-9 pathway is also important in the tumor microenvironment and development of cancer immunotherapy that inhibits them is very important.
|
